News Release

Paxlovid and COVID-19 mortality and hospitalization among patients with vulnerability to COVID-19 complications

JAMA Network Open

Peer-Reviewed Publication

JAMA Network

About The Study: In this study of 6,866 individuals with COVID-19, nirmatrelvir and ritonavir (Paxlovid [Pfizer]) treatment was associated with reduced risk of COVID-19 hospitalization or death in clinically extremely vulnerable individuals, with the greatest benefit observed in severely immunocompromised individuals. No reduction in the primary outcome (death from any cause or emergency hospitalization with COVID-19 within 28 days) was observed in lower-risk individuals, including those age 70 or older without serious comorbidities. 

Authors: Colin R. Dormuth, Sc.D., of the University of British Columbia in Vancouver, is the corresponding author. 

To access the embargoed study: Visit our For The Media website at this link 


Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time

About JAMA Network Open: JAMA Network Open is an online-only open access general medical journal from the JAMA Network. On weekdays, the journal publishes peer-reviewed clinical research and commentary in more than 40 medical and health subject areas. Every article is free online from the day of publication. 

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.